Get instant alerts when news breaks on your stocks. Claim your one week free trial for StreetInsider Premium here.

Highlights the company’s progress towards becoming a pure RNA business and technology strategy and entering the multi-billion TAM

HAMILTON, BERMUDA/ACCESSWIRE/May 18, 2022 / Altamira Therapeutics Ltd. (NASDAQ: CYTO), a company dedicated to developing therapies that address significant unmet medical needs, today released a letter to shareholders highlighting the company’s recent achievements and its outlook for 2022.

Company highlights include:

• Altamira’s Pivot to Become a Pure-Play RNA Therapeutics Company
• The progress of its RNA business and technology strategy to enter the multi-billion dollar Total Addressable Market (TAM) $50 billion TAM
• The strategy with its RNA AM-401 program to achieve its first clinical proof of concept targeting KRAS-induced cancers
• The rapid global expansion and commercialization of its drug-free nasal spray Bentrio
• Timeline of scheduled readings from several ongoing Bentrio clinical trials
• Upcoming clinical data from its AM-125 nasal spray program for vertigo
• Next regulatory steps

“Over the past few months, we have made tremendous progress in pivoting our business toward pure RNA-based therapeutic gaming,” said Thomas Meyer, Founder, CEO and Chairman of Altamira. “We laid the foundation by developing our proprietary OligoPhore^MT / Semaphore^MT platforms for extrahepatic RNA delivery and are progressing the preclinical development of our AM-401 for the treatment of KRAS-induced cancers.

Along with the transition of our business, we continued to invest in our non-RNA legacy programs and drive the towards several important milestones. Our drug-free Bentrio nasal spray continues to expand its global market footprint in more than 20 countries as we progress through three clinical trials. Based on positive interim clinical data for our vertigo drug AM-125 nasal spray, we look forward to the next readout of our Phase 2 clinical trial. We plan to divest or divest all legacy assets here the end of 2022 in order to more fully realize their value and become a pure play RNA company. »

To read the letter to shareholders, please visit: https://ir.altamiratherapeutics.com/

About Altamira Therapeutics

Altamira Therapeutics (NASDAQ: CYTO) is dedicated to developing therapeutic products that address significant unmet medical needs. The Company is currently active in three fields: the development of RNA therapeutics for extrahepatic therapeutic targets (OligoPhore” / SemaPhore” platforms; preclinical), nasal sprays for protection against airborne viruses and allergens (Bentrio; commercial) or the treatment vertigo (AM -125; Phase 2), and the development of therapies for the intratympanic treatment of tinnitus or hearing loss (Keyzilen® and Sonsuvi®, Phase 3). Founded in 2003, Altamira is headquartered in Hamilton, Bermuda, with principal operations in Basel, Switzerland. For more information visit: https://altamiratherapeutics.com.

Forward-looking statements

This press release may contain statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than statements of fact statements and may include statements that address future operational, financial or business performance or Altamira Therapeutics’ strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may”, “could”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “estimates”, “predicts”, “plans”, “potential”, “outlook” or “continues”, or the negative form of these terms or any other comparable terminology. Forward-looking statements are based on the current expectations and beliefs of management and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by such statements.These risks and uncertainties include, but are not limited to, approval, timing and commercial success of AM-301, Altamira Therapeutics’ need and ability to obtain substantial additional funds to pursue the development of its product candidates, the timing and the conduct of clinical trials of Altamira Therapeutics’ product candidates, the clinical utility of Altamira Therapeutics’ product candidates, the timing or likelihood of regulatory filings and approvals, Altamira Therapeutics’ intellectual property position and the financial position of Altamira Therapeutics, including the impact of any acquisitions, divestitures, partnerships, licensing transactions or changes in the capital structure of Altamira Therapeutics, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under “Risk Factors” in Altamira Therapeutics’ Annual Report on Form 20-F for the fiscal year ended December 31, 2021, and in other documents filed by Altamira Therapeutics with the SEC, which are available free of charge on the Securities Exchange Commission’s website at: www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira Therapeutics or persons acting on behalf of Altamira Therapeutics are expressly qualified in their entirety by reference to such risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Altamira Therapeutics undertakes no obligation to update them in light of new information, future developments or otherwise, except as required by applicable law. required.

Investor contacts:
[email protected]
800-460-0183

THE SOURCE: Altamira Therapeutic

See the source version on accesswire.com:
https://www.accesswire.com/701814/Altamira-Therapeutics-Issues-Shareholder-Letter